News

Although many patients with Huntington’s disease (HD) experience pain, they report this problem has less of an effect on their daily lives than it does for the general population, a review study has found. Due to the areas of the brain affected in Huntington’s, patients…

DYST 201, a gene therapy targeting the mutated forms of the gene responsible for Huntington’s disease, has shown promising results, Dystrogen Therapeutics announced. The results will be presented at two meetings in Krakow, Poland — the July 6-11 44th FEBS Congress and the June 11-16 24th Annual Meeting of the RNA Society.

The U.S. Food and Drug Administration (FDA) has given fast track designation to AMT-130, uniQure’s gene therapy candidate for the treatment of Huntington’s disease. The designation helps to speed the development, testing, and review of therapies for serious diseases with high unmet medical need. “Achieving Fast Track Designation from the…

Aiming to raise awareness about Huntington’s disease (HD) while also commemorating a decade of community service, HD Reach presented its annual Education Day April 6 in Raleigh, North Carolina. Themed “Looking Back, Reaching Forward,” the event was held at the McKimmon Center at North Carolina State University. The non-profit…

Genistein, a potent stimulator of cells’ natural “cleaning system” was able to reduce the levels of mutant huntingtin protein in skin cells from Huntington’s disease patients, a study has found. The study, “Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington’s disease patients,” was published in…

Combining stem cell and gene therapy can ease symptoms and lengthen survival time in a mouse model of Huntington’s disease, according to recent research. The study, “Combination of stem cell and gene therapy ameliorates symptoms in Huntington’s disease mice,” was published in the journal Regenerative Medicine. Huntington’s is caused…

Active psychiatric disorders are associated with increased risk of suicidal behaviors among Huntington’s patients participating in clinical trials, a large-scale study suggests. The study, “Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial,” was published in Neurology. Huntington’s disease is mostly recognized for…

Practicing contemporary dance can improve motor function in people with Huntington’s disease, a new study has found. Titled “Contemporary Dance Practice Improves Motor Function and Body Representation in Huntington’s Disease: A Pilot Study,” the study was published in the Journal of Huntington’s Disease. There is overwhelming evidence…

A software known as “DriveSafe DriveAware” can help evaluate if patients with Huntington’s disease still have the cognitive fitness needed to safely drive a car, a pilot study shows. However, to increase the accuracy of the software some improvements should be made to better fit the profile of patients…

The U.S. Food and Drug Administration (FDA) has issued a letter of support encouraging sRNAlytics to further develop its sRNA-FIND platform for discovering and monitoring variants of small RNA molecules that may work as biomarkers for tracking progression of Huntington’s disease decades before symptom onset. In addition, these biomarkers may…